Table 2.
Neurohumoral Data Following M‐ANP, Nitroglycerin, or Vehicle Administration
| Treatment | MLVD | MLVD+HTN | Vehicle, M‐ANP, or NTG Infusion | Post Vehicle, M‐ANP, or NTG Infusion | ||
|---|---|---|---|---|---|---|
| 30 Minutes | 60 Minutes | 120 Minutes | ||||
| ANG II, pg/mL | ||||||
| Vehicle | 43±9 | 181±31* | 245±29* | 191±25* | 174±37.1* | 171±27* |
| M‐ANP | 29±7 | 213±18* | 222±39* | 201±37* | 273±43* | 185±15* |
| NTG | 39±11 | 183±20* | 209±52* | 249±51* | 165±11* | 184±23* |
| Plasma ANP§, pg/mL | ||||||
| Vehicle | 193±76 | 402±185* | 435±125* | 428±107* | 431±103* | 547±136* |
| M‐ANP | 173±53 | 404±182* | 1863±464*†‡ | 735±180*‡ | 408±165 | 230±91 |
| NTG | 204±41 | 299±22* | 190±35‡ | 200±27‡ | 247±36 | 264±43 |
| Plasma cGMP§, pg/mL | ||||||
| Vehicle | 11.3±1.1 | 13.9±1.0* | 14.4±1.3* | 14.1±1.3* | 14.4±1.7* | 14.9±1.9* |
| M‐ANP | 9.9±0.9 | 11.7±1.4* | 44.7±2.1*†‡ | 33.3±1.9*†‡ | 20.0±1.3*†‡ | 11.9±1.3 |
| NTG | 9.5±0.7 | 12.8±0.5* | 11.3±0.6 | 10.2±0.5† | 10.1±0.4† | 11.4±0.7 |
| Urine ANP§, pg/min | ||||||
| Vehicle | 22.5±2.9 | 44.3±12.0* | 39.1±6.6* | 44.6±7.8* | 47.3±8.0* | 44.2±8.0* |
| M‐ANP | 30.9±11.5 | 64.8±15.8* | 195.2±60.7*†‡ | 155.1±50.0*†‡ | 57.5±17.2 | 59.9±28.4 |
| NTG | 33.6±9.7 | 49.6±7.5* | 44.1±13.4 | 41.8±17.9 | 43.1±18.4 | 64.4±26.2 |
| Renal cGMP generation§, pmol/min | ||||||
| Vehicle | 361±38 | 574±105 | 631±104 | 590±131 | 641±109 | 587±98 |
| M‐ANP | 288±37 | 384±55 | 2514±234*†‡ | 1760±268*†‡ | 769±62†‡ | 430±56 |
| NTG | 278±18 | 435±63 | 346±28 | 303±20 | 332±35 | 418±65* |
| Filtered cGMP§, pmol/min | ||||||
| Vehicle | 492±42 | 540±205 | 454±66 | 630±126 | 593±76 | 756±136 |
| M‐ANP | 499±77 | 570±124 | 5451±1098*†‡ | 5156±1120*†‡ | 1762±181*†‡ | 914±147 |
| NTG | 507±55 | 433±110 | 524±64 | 509±56 | 441±37 | 739±75* |
| Plasma aldosterone, ng/dL | ||||||
| Vehicle | 13.1±3.2 | 30.9±3.7* | 38.1±2.0*† | 40.9±2.6*† | 39.4±3.1*† | 45.3±4.5*† |
| M‐ANP | 9.8±1.4 | 31.5±3.0* | 23.2±2.0*† | 26.3±2.5* | 37.9±3.4* | 46.8±3.6*† |
| NTG | 11.1±3.8 | 27.0±5.5* | 34.7±6.0* | 37.4±6.0*† | 39.5±5.7*† | 41.8±4.2*† |
ANG II indicates angiotensin II; ANOVA, analysis of variance; cGMP, cyclic guanosine monophosphate; M‐ANP, M‐atrial natriuretic peptide; MLVD, mild left ventricular dysfunction; MLVD+HTN, MLVD and angiotensin II induced hypertension; NTG, nitroglycerin.
*P<0.05 vs MLVD and †P<0.05 vs MLVD+HTN, 2‐way ANOVA with pairwise comparison of individual time points within groups using the Tukey HSD methods.
‡P<0.05 vs NTG at a specific time point, 2‐way ANOVA with Bonferroni posttests.
§P interaction <0.05 for the main effects of treatment and time between M‐ANP vs NTG, 2‐way ANOVA.